Unichem Laboratories' Q3 FY 2025-26 Quarterly Results
- 06 Feb 2026
Result Summary
- Unichem Laboratories Ltd reported a 11.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 2.5%.
- Its expenses for the quarter were down by 6.8% QoQ and up 6.2% YoY.
- The net profit decreased 2322.8% QoQ and increased 356.9% YoY.
- The earnings per share (EPS) of Unichem Laboratories Ltd stood at 37.47 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 532.97 | 599.93 | 546.71 | -11.2% | -2.5% |
Total Expenses | 515.06 | 552.49 | 484.86 | -6.8% | 6.2% |
Profit Before Tax | 293.43 | -10.82 | 61.85 | -2811.9% | 374.4% |
Tax | 29.14 | 1.07 | 4.00 | 2623.4% | 628.5% |
Profit After Tax | 264.29 | -11.89 | 57.85 | -2322.8% | 356.9% |
Earnings Per Share | 37.47 | -1.69 | 8.19 | -2317.2% | 357.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Unichem Laboratories Ltd is a well-established pharmaceutical company primarily engaged in the development, manufacture, and marketing of pharmaceutical products. The company is known for its comprehensive range of formulations, including tablets, capsules, injectables, and topical treatments. Unichem Laboratories operates in the pharmaceutical industry, which is characterized by rigorous regulatory standards and high investment in research and development. Recent major developments in the industry include increased focus on generic drug production and expansion into new markets. However, specific recent developments for Unichem Laboratories Ltd are not available in the provided data.
Revenue
In the third quarter of the fiscal year 2026, Unichem Laboratories Ltd reported total income of ₹532.97 crores. This represents an 11.2% decrease from the previous quarter (Q2FY26), where the company recorded a total income of ₹599.93 crores. Year-over-year, there was a 2.5% decline in total income compared to Q3FY25, when the income was ₹546.71 crores. The data indicates fluctuations in revenue, demonstrating a downward trend both sequentially and annually for this period. The factors contributing to these fluctuations are not detailed in the provided data.
Profitability
The profitability of Unichem Laboratories Ltd saw a significant improvement in Q3FY26, with a Profit Before Tax (PBT) of ₹293.43 crores, compared to a loss of ₹10.82 crores in Q2FY26. This marks a drastic quarter-over-quarter change of 2811.9%. Year-over-year, the PBT increased by 374.4% from ₹61.85 crores in Q3FY25. The company's Profit After Tax (PAT) also experienced a substantial rise to ₹264.29 crores in Q3FY26, compared to a loss of ₹11.89 crores in the previous quarter, resulting in a 2322.8% QoQ change. The YoY increase in PAT was 356.9%, up from ₹57.85 crores in Q3FY25. Earnings per share (EPS) followed a similar trend, increasing from -₹1.69 in Q2FY26 to ₹37.47 in Q3FY26, and up from ₹8.19 in Q3FY25.
Operating Metrics
The operating expenses of Unichem Laboratories Ltd decreased by 6.8% quarter-over-quarter, from ₹552.49 crores in Q2FY26 to ₹515.06 crores in Q3FY26. Year-over-year, total expenses increased by 6.2% compared to ₹484.86 crores in Q3FY25. The tax expense for Q3FY26 was ₹29.14 crores, showing a significant increase from ₹1.07 crores in Q2FY26, and an increase from ₹4.00 crores in Q3FY25. This indicates substantial changes in the tax liabilities of the company, both sequentially and annually. The data provided does not include additional operating metrics, such as liquidity ratios or leverage ratios, which are typically used to assess the financial health and operational efficiency of a company.